FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely therapy and endocrinology, and may be applicable as a lipid, carbohydrate and protein normalising drug in treating type II diabetes mellitus, atherosclerosis and metabolic syndrome. That is ensured by adding the integrating therapy with the drug Uglanex.
EFFECT: invention provides effective treatment of said pathological conditions ensured by reducing a cholesterol level, an atherogenicity index, blood sugar, insulin resistance and albuminuria.
3 tbl
Title | Year | Author | Number |
---|---|---|---|
COMPOSITION FOR METABOLIC SYNDROME CORRECTION | 2016 |
|
RU2616241C1 |
METHOD FOR INSULIN RESISTANCE CORRECTION IN METABOLIC SYNDROME | 2009 |
|
RU2402326C1 |
HEPATOPROTECTOR FOR TREATING NON-ALCOHOLIC LIVER DISEASE IN TYPE 2 DIABETES MELLITUS | 2013 |
|
RU2537227C1 |
METHOD OF TREATMENT AND PREVENTION OF COMPLICATIONS IN DIABETES MELLITUS TYPE TWO | 2009 |
|
RU2401114C1 |
METHOD OF TREATING NON-ALCOHOLIC LIVER DISEASE ACCOMPANYING TYPE 2 DIABETES MELLITUS | 2013 |
|
RU2538221C1 |
METHOD FOR METABOLIC SYNDROME CORRECTION WITH USE OF MARE'S MILK AND HYPOBAROTHERAPY | 2012 |
|
RU2472514C1 |
ELIXIR SHOWING TOTAL TONIC AND ADAPTOGENIC ACTION | 2000 |
|
RU2171113C1 |
METHOD DETERMINING TACTICS OF CARRYING OUT OF MEDICAL ACTIONS AT PATIENTS WITH METABOLIC SYNDROME AGAINST ARTERIAL HYPERTENSIA | 2007 |
|
RU2337612C1 |
METHOD OF TREATING METABOLIC SYNDROME X | 1998 |
|
RU2143902C1 |
METHOD FOR TREATING PREDIABETES IN PERSONS WITH EXTERNAL EATING BEHAVIOR | 2022 |
|
RU2805361C1 |
Authors
Dates
2012-09-20—Published
2011-05-20—Filed